Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistMedClub by Dr. Jenn was cited for unlawfully selling unapproved and misbranded compounded drug products, specifically retatrutide and semaglutide, over the internet without FDA approval in violation of sections 505(a), 502(f)(1), 301(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act. The company's compounded semaglutide products also contained false or misleading claims in violation of sections 502(a) and 502(bb). The violations were identified during an FDA review of the company's website (drjennpb.com) conducted in June 2025, revealing that the products failed to meet exemption requirements for compounded drugs, including lacking proper FDA oversight and adequate labeling with directions for use.